Trxade Group Inc. (NASDAQ: MEDS) was featured in a
recent equity research report published by Dougherty & Company LLC. The
report reads, “We reiterate our Buy rating and $12 Price Target on MEDS
following Q1 results that beat expectations. As the only estimate on the
Street, we note that revenue, EBITDA and EPS were each ahead of our forecast.
MEDS added 305 new pharmacy registrations which was in line with our forecast
of 300. We were pleased also with the “same-store” growth of pharmacy
prescription volume which was up 14% y/y and drove the upside to our model. Results
were especially strong in light of the COVID pandemic which impacted results in
the last 3 weeks of March. We are increasing estimates for 2020 and continue to
recommend the name.”
To request access to the full report, visit http://ibn.fm/csjD4
About Trxade Group Inc.
Headquartered in Tampa, Florida, Trxade Group Inc. is an
integrated drug procurement, delivery and healthcare platform that enables
price transparency and increased profit margins to buyers and sellers of
pharmaceuticals, makes healthcare services affordable and accessible across all
50 states, and steps in to meet today’s immediate demands. Founded in 2010,
Trxade Group is comprised of four synergistic operating platforms; the Trxade
B2B trading platform with 12,100 registered pharmacies, a licensed virtual
Wholesaler, affordable healthcare via its Bonum Health app or web-based
telehealth services, and same day or mail order pharmacy delivery capabilities
via its DelivMeds app featuring its extensive nationwide distribution network.
For additional information, please visit www.Trxade.com.
NOTE TO INVESTORS: The latest news and updates
relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
